Biothorpe Research
Biothorpe is working to research and develop innovative treatments that could reach millions of patients. From Acute Myelogenous Leukemia to B-Cell Lymphoma to Chronic Lymphocytic Leukemia, our research is helping to shape the future of cancer therapeutics.
Our research and development operations are closely supervised by Biothorpe’s Chairman and Chief Executive Officer, Alan D. Schreiber, M.D. Our licensed patent portfolio includes U.S. and international patents, all of which have been licensed exclusively from our parent company, ZaBeCor Pharmaceuticals. We believe that our patent portfolio features potential groundbreaking advances in cancer therapeutics.
Dr. Schreiber was among the first to identify a molecule (Syk kinase) in inflammatory cells that is required for the release of mediators and cytokines that cause organ damage. Syk kinase is an early and essential signal in the network that leads to inflammation. There are no known alternate paths around Syk kinase, which is unusual in the intracellular signaling cascade, so removal of Syk kinase is reliable in inhibiting inflammation and resulting tissue damage.
Dr. Schreiber was among the first to determine that inhibition of the synthesis of this molecule dramatically halts the release of a wide range of inflammatory mediators. Further, he developed a molecular approach using a unique siRNA and antisense DNA treatments to prevent the production of Syk kinase.
Recent data suggest that Syk kinase is required for the proliferation of malignant cells in several blood cancers. These include Acute Myelogenous Leukemia, B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Thus, targeting Syk kinase with siRNA and other oligonucleotides represents a novel therapeutic approach for these cancers. Biothorpe has the exclusive worldwide intellectual property rights for the treatment of patients with siRNA and other oligonucleotides directed at Syk kinase.